Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
EIK1004 Monotherapy in Advanced Solid Tumors
NCT06907043Phase 2Recruiting
- Sponsor
- Eikon Therapeutics
- Start
- Apr 2025
- Primary completion
- Dec 2028
- Modality
- Small Molecules
- Countries
- 3
01
Overview
Phase 2, open-label trial of EIK1004 in solid tumor (advanced stage), breast cancer, ovarian cancer and 2 more (2 arms), sponsored by Eikon Therapeutics. Primary endpoints: Number of Participants who experience a Dose-Limiting Toxicity up to 28 days and Number of participants with adverse events. Started Apr 2025; status: recruiting.
02
Drugs
EIK1004
03
Conditions
solid tumor (advanced stage)breast cancerovarian cancerprostate cancer (PCa)pancreatic cancer (PC)
Beyond the preview
Go deeper on NCT06907043.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06907043.